Literature DB >> 28401358

mRNA Cancer Vaccines-Messages that Prevail.

Christian Grunwitz1, Lena M Kranz2.   

Abstract

During the last decade, mRNA became increasingly recognized as a versatile tool for the development of new innovative therapeutics. Especially for vaccine development, mRNA is of outstanding interest and numerous clinical trials have been initiated. Strikingly, all of these studies have proven that large-scale GMP production of mRNA is feasible and concordantly report a favorable safety profile of mRNA vaccines. Induction of T-cell immunity is a multi-faceted process comprising antigen acquisition, antigen processing and presentation, as well as immune stimulation. The effectiveness of mRNA vaccines is critically dependent on making the antigen(s) of interest available to professional antigen-presenting cells, especially DCs. Efficient delivery of mRNA into DCs in vivo remains a major challenge in the mRNA vaccine field. This review summarizes the principles of mRNA vaccines and highlights the importance of in vivo mRNA delivery and recent advances in harnessing their therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28401358     DOI: 10.1007/82_2017_509

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  21 in total

Review 1.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

Review 2.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

Review 3.  Comparison of DNA and mRNA vaccines against cancer.

Authors:  Zohreh Jahanafrooz; Behzad Baradaran; Jafar Mosafer; Mahmoud Hashemzaei; Tayebeh Rezaei; Ahad Mokhtarzadeh; Michael R Hamblin
Journal:  Drug Discov Today       Date:  2019-12-13       Impact factor: 7.851

Review 4.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

5.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

Review 6.  Toward rational vaccine engineering.

Authors:  Yashavantha L Vishweshwaraiah; Nikolay V Dokholyan
Journal:  Adv Drug Deliv Rev       Date:  2022-02-09       Impact factor: 15.470

7.  Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.

Authors:  Tong Lu; Ran Xu; Cheng-Hao Wang; Jia-Ying Zhao; Bo Peng; Jun Wang; Lin-You Zhang
Journal:  Front Genet       Date:  2022-06-06       Impact factor: 4.772

Review 8.  Targeting Head and Neck Cancer by Vaccination.

Authors:  Chuan Wang; James Dickie; Ruhcha V Sutavani; Catherine Pointer; Gareth J Thomas; Natalia Savelyeva
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

Review 9.  Advances in mRNA Vaccines for Infectious Diseases.

Authors:  Cuiling Zhang; Giulietta Maruggi; Hu Shan; Junwei Li
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

10.  Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes.

Authors:  Lien Van Hoecke; Sandra Van Lint; Kenny Roose; Alexander Van Parys; Peter Vandenabeele; Johan Grooten; Jan Tavernier; Stefaan De Koker; Xavier Saelens
Journal:  Nat Commun       Date:  2018-08-24       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.